Treatment with low‐dose nintedanib and tacrolimus in patients with progressive fibrosing interstitial lung diseases with anti‐ARS antibody‐positive dermatomyositis
Abstract Nintedanib has been demonstrated to inhibit the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases (PF‐ILD) at a dose of 200 or 300 mg/day in the INBUILD trial. Although concomitant use of nintedanib with P‐glycoprotein inhibitors reporte...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Wiley
2024-07-01
|
| Rangatū: | Respirology Case Reports |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1002/rcr2.1428 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|